Contact
Gabriel Nistor
www.linkedin.com/in/gabriel- Chief Science Officer, AiVita Biomedical
nistor-5b637723 (LinkedIn) Orange County
www.aivitabiomedical.com
(Company)
Summary
Top Skills Broad, multidisciplinary knowledge and skills in all science areas,
Cancer immunology with main expertise in biological and medical fields. My work is
Stem Cells marked by scientific method, creativity, innovation, critical thinking,
Cell Biology analysis, information synthesis and personal expression. I promote
leadership by integrity, ethical judgment, personal example, clear
Languages communication and skill transfer. I identify opportunities, translate to
English (Native or Bilingual) business value and anticipate the challenges of complex scientific
Romanian (Native or Bilingual) discoveries.
Hungarian (Native or Bilingual)

Certifications Experience
Amateur Radio License
AIVITA Biomedical Inc
Publications Chief Science Officer
January 2016 - Present (5 years 3 months)
Randomized phase II trial of
Irvine, California
autologous dendritic cell vaccines
versus autologous tumor cell
vaccines in metastatic melanoma:
5-year follow up and additional Caladrius Biosciences, Inc.
analyses. Vice President, Research
Derivation of oligodendrocyte May 2014 - January 2016 (1 year 9 months)
progenitor cells from human Irvine, CA
embryonic stem cells
The most valued accomplishment is building my dedicated, highly skilled and
Human Stem Cell-Derived Skin
Progenitors Produce Alpha 2- versatile team capable of overcoming any given challenge.
HS Glycoprotein (Fetuin): A Created a quality by design environment compliant with modern cGMP, to
Revolutionary Cosmetic Ingredient.
support the research, development and manufacturing troubleshooting in
Histological and functional benefit
following transplantation of motor phase III clinical trial for advanced stage melanoma using autologous tumor
neuron progenitors to the injured rat initiating cells and autologous dendritic cells.
spinal cord.
Using patient samples, lead the investigation of the mechanism of action
Cancer stem cell antigen-based
in cancer immune-therapy. Developed final product potency assay and
vaccines: the preferred strategy for
active specific immunotherapy of discovered clinical predictive and efficacy biomarkers for dendritic cell based
metastatic melanoma?
immune-therapy that could complement the current approaches based on
checkpoint inhibitors. Using complex investigative methods that included
Patents
exomic analysis of the purified tumor "stem" cells and mixed lymphocyte
High purity ovarian cancer stem reactions elucidated multiple pathways of immune response to strong or weak
cells for active autologous immune
therapy
  Page 1 of 3

Bioreactor Cartridge and System
Immunogenic compositions prepared
from tumor cells derived from
peripheral blood and originating from
a solid tumor and their use
Stem cell compositions for cosmetic
and dermatologic use
Neural cell purification for
transplantation
 
antigens resulted from cancer associated mutations equally suggestive for
immune-escape and tumorigenesis.
Investigated feasibility and established methods for manufacturing of purified
tumor stem cells as antigen sources for autologous immune-therapy approach
in other types of cancer (hepatocellular carcinoma, ovarian cancer, non-small
lung cancer, glioblastoma etc).
Successful isolated and expanded circulating tumor cells from cancer patients
and identified factors that allow survival of the cells in routine blood samples.
Developed proprietary reagents and methods that enabled consistent isolation
of cancer "stem" cells from bulk tumors and rapid expansion for use as
antigenic sources.
Filed multiple patent applications and actively involved in developing
company's IP portfolio strategy and in the patent prosecution process.
Submitted and awarded multiple grants (CIRM, NIH) totaling over $20 millions.
California Stem Cell, Inc.
Vice President, Research and Development
2006 - 2014 (8 years)
Adopted modern principles of product development based on quality by
design: establishing critical quality attributes, process mapping, cause and
effect analysis, design of experiments, risk assessment and management.
Developed and patented reagent, manufacturing process, in-process control
and releasing criteria for stem cell derivates suitable for cell-replacement
therapies
Coordinating the development of new pipelines of cell products with application
in research and clinic.
Participated in IND meetings for phase I for SMA stem cell therapy and for
phase III Melanoma immunotherapy application
Presented R&D pipeline and patent portfolio for investors in various
fundraising occasions
Developed methods for differentiating human embryonic stem cells in high
purity populations of oligodendrocytes, neurons, cardiomyocytes, hepatocytes.
Developed a concept and conditions for stemness maintenance, stem cell
niche and differentiation mechanism of human embryonic stem cells, used
successfully to grow very large quantities of cells with regulatory compliance.
Developed in vitro human neuro-muscular system from stem cell derived motor
neurons and primary myoblasts differentiated to skeletal muscle.
Identified factors that are influencing the stem cell niche aging or renewal,
that contribute to the maintenance of healthy organisms with applicability in
immune-modulation, aging and cosmetics
Page 2 of 3
   

Transferred proof of concept immune-therapy technology from Hoag Hospital

to California Stem Cell Inc manufacturing. Improved manufacturing for purified
tumor initiating cells with a new set of reagents and methods designed for high
success rate.
Developed patenting strategy for the manufacturing and final product
applications in various cancers
Actively participated with corporate legal office in pre-grant patent prosecution
process for initial filings and multiple divisional and international filings.

University California Irvine

Postdoctoral Research
January 2003 - 2006 (3 years)

County Hospital Tg.Mures

M.D.
1993 - 1999 (6 years)

Education
University of California, Irvine
Postdoctoral fellow, Neuroscience, Stem cells · (2003 - 2006)

University of Medicine and Pharmacy Tg Mures, Romania

medical doctor  · (1987 - 1993)

  Page 3 of 3